164 filings
Page 2 of 9
6-K
0mhlow
2 Nov 20
Trillium Therapeutics Announces Formation of Scientific Advisory Board
4:15pm
6-K
z9sooevo6jsby6l
5 Oct 20
Trillium Therapeutics Receives Notices of Allowance from U.S. Patent and Trademark Office
7:14am
6-K
dvzgjd0w1i8 3l2zh5
18 Sep 20
Trillium Therapeutics Appoints Michael Kamarck, PH.D., to Its Board of Directors
7:19am
6-K
1okbfp08kdm xq75b
16 Sep 20
Trillium Closes US$150 Million Public Offering of Common Shares
4:30pm
6-K
uovexyx
11 Sep 20
Trillium Announces Pricing of US$130 Million Public Offering of Common Shares
12:00am
6-K
nfz235e m8cuds
9 Sep 20
Trillium Announces Proposed Public Offering of Common Shares
4:01pm
6-K
w9j1qgg1lm
9 Sep 20
Current report (foreign)
12:00am
6-K
k397 hu4qmwd137fi
8 Sep 20
Trillium Therapeutics Announces Updated Data from Its Ongoing TTI-622 and TTI-621 Dose Escalation Studies
4:05pm
6-K
9z9txj7 g5bwe95ih
12 Aug 20
Consolidated Financial Statements
7:04am
6-K
o00jndpqxn5c
30 Jul 20
Trillium Therapeutics Provides Update on Phase 1 Study of TTI-621 and Dose Escalation to 2.0 MG/KG Level
7:29am
6-K
qze7j
6 Jul 20
Current report (foreign)
7:10am
6-K
gyhdvdn82k1jt
29 May 20
Trillium Therapeutics Provides Update on the Phase I
8:00am
6-K
oqe187t6
26 May 20
Annual General and Special Meeting
7:01am
6-K
9xn5uerl4tshtmw40vnd
15 May 20
Consolidated Financial Statements
5:00pm
6-K
2ffrt5z md00td94
13 May 20
Current report (foreign)
7:04am
6-K
w9r 0u8p72zo92s
6 May 20
Trillium Therapeutics Announces "At-the-market" Equity Program
7:12am
6-K
xtm0zx
5 May 20
Current report (foreign)
5:21pm
6-K
av6y2dzp1b1f
23 Apr 20
Current report (foreign)
4:21pm
6-K
zgi5u8r18ugl
8 Apr 20
Trillium Therapeutics Provides Business Update In Response to the COVID-19 Pandemic
7:08am
6-K
o3rxlc4qvmnu3et9
10 Mar 20
Trillium Therapeutics Reports Annual Financial and Operating Results
7:09am